The Chapman et al. study identified two mutations in the BLIMP1 gene from their 38 samples, and as loss-of-function mutations in BLIMP1 are known to occur in diffuse large B-cell lymphoma [121], this suggests BLIMP1 mutations may be of pathogenic importance to myeloma. This evidence concerns the gene PRDM1 and diffuse large B-cell lymphoma.